Sotera Health Raises FY 2026 Outlook on Strong Q2 Growth
Event summary
- Q2 2026 net revenues increased by 9.2% year-over-year, or 8.0% on a constant currency basis.
- Net income surged to $54 million from $8 million in Q2 2025, with Adjusted EBITDA up 10.0%.
- All three business units—Sterigenics, Nordion, and Nelson Labs—showed revenue growth.
- Company raised FY 2026 net revenues growth outlook to 5.25%-6.75% from previous guidance.
- Achieved long-term Net Leverage Ratio target of 2.0x-3.0x as of June 30, 2026.
The big picture
Sotera Health's strong Q2 performance reflects the essential nature of its sterilization and lab testing services in healthcare. The company's ability to raise its FY 2026 outlook signals confidence in its strategic execution, particularly amid ongoing inflationary pressures and regulatory challenges. With a diversified business model and improved financial leverage, Sotera Health is positioning itself for sustained growth in a highly regulated industry.
What we're watching
- Revenue Diversification
- How the company will balance growth across Sterigenics, Nordion, and Nelson Labs to sustain momentum.
- Operational Efficiency
- Whether cost management can offset inflationary pressures in the second half of 2026.
- Regulatory Compliance
- The impact of evolving environmental and health regulations on Sterigenics' operations.
Related topics